The performance of companies tied to the drug's history presents a challenging investment picture . While the initial success generated substantial gains, generic copies have significantly eroded revenue. Investing in connected pharmaceutical businesses now requires a thorough assessment of proprietary rights , evolving healthcare trends , and the